Tumours with higher expression of SLFN11, RAD51C, CDK2, LIG3 and POLA1 were associated with better prognosis (Fig. 1b; Supplementary Fig. S1c), whereas tumours with increased expression of RSR genes such as Cyclin E1/2, CHEK1/2, RAD51, ATR, DCLRE1/ARTEMIS and RPA3 alone or in combination had worse prognosis, making them ideal novel therapeutic targets. Here, RAD51 is linked to neoplasm.